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ABSTRACT: Multimodal nanoparticulate materials are de-
scribed, oﬀering magnetic, radionuclide, and ﬂuorescent imaging
capabilities to exploit the complementary advantages of magnetic
resonance imaging (MRI), positron emission tomography/single-
photon emission commuted tomography (PET/SPECT), and
optical imaging. They comprise Fe3O4@NaYF4 core/shell
nanoparticles (NPs) with diﬀerent cation dopants in the shell
or core, including Co0.16Fe2.84O4@NaYF4(Yb, Er) and Fe3O4@
NaYF4(Yb, Tm). These NPs are stabilized by bisphosphonate
polyethylene glycol conjugates (BP-PEG), and then show a high
transverse relaxivity (r2) up to 326 mM
−1 s−1 at 3T, a high aﬃnity
to [18F]-ﬂuoride or radiometal-bisphosphonate conjugates (e.g., 64Cu and 99mTc), and ﬂuorescent emissions from 500 to 800 nm
under excitation at 980 nm. The biodistribution of intravenously administered particles determined by PET/MR imaging
suggests that negatively charged Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG (10K) NPs cleared from the blood pool more slowly
than positively charged NPs Fe3O4@NaYF4(Yb, Tm)-BP-PEG (2K). Preliminary results in sentinel lymph node imaging in mice
indicate the advantages of multimodal imaging.
■ INTRODUCTION
The potential clinical and biomedical application of synergistic
combinations of magnetic resonance imaging (MRI) with other
biomedical imaging modalities, especially positron emission
tomography (PET) and optical imaging, has become an
emerging topic in the last ten years.1−3 Combinations of
imaging modalities have the potential to overcome the
respective limitations of the individual imaging techniques
and provide more accurate and complete physiological and
anatomical information for diagnosis and therapy.4−7 In certain
applications, the combination of imaging techniques into a
single contrast agent could also oﬀer the beneﬁts of a reduced
dose of contrast agent, a shorter procedure time for both
patients and scanners, and the assurance that the diﬀerent scans
reﬂect contrast located in the same physiological conditions and
spatial position.8,9 Compared with small molecules or
bioconjugates widely used in research and the clinic, nano-
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particles (NPs) allow an enhanced imaging signal due to their
high payload, as well as a high avidity via multiple targeting
ligands attached to their surface.10 In addition, T2 or T2*
contrast in MRI inherently requires that the contrast agents are
particulate. As ﬂuorescent probes, inorganic NPs can not only
provide more intense and stable emissions (with peaks tunable
from the visible to the near-infrared region), but are generally
more thermally stable under laser illumination than organic
molecular dyes.9,11 The majority of current multimodality
contrast agents are based on superparamagnetic iron oxide
NPs,12−14 while a few examples of Gd15,16 or Mn17 containing
NPs have also been reported. Since Weissleder et al.18 reported
their pioneering work on multimodal imaging, combinations of
NPs and functional polymers19 or polydentate ligands8,20,21
have been widely applied to obtain multifunctional agents.14,15
An alternative approach is hybrid inorganic nanocomposites
containing two materials with diﬀerent properties, such as
Fe3O4@NaGdF4 NPs,
22 NaYF4@FexOy,
23 and Fe3O4@LnF3.
24
For these hybrid inorganic NPs to be used as multimodal
imaging contrast, however, a well-deﬁned core−shell structure
is crucial to avoid the possibility that some fractions of the NPs
behave diﬀerently from other fractions, and as a result diﬀerent
imaging modalities reﬂect the contrast located in diﬀerent
spatial positions.
In this report, we set out to design a trimodal system
comprising a magnetic and a ﬂuorescent component with rapid,
facile, and eﬃcient radiolabeling under sterile, GMP (Good
Manufacturing Practice) conditions with minimal manipulation.
Ideally, the system must have a well-deﬁned structure to ensure
that the properties do not vary between particles and that the
signals of diﬀerent modalities do not come from the diﬀerent
particle types with potentially diﬀerent in vivo locations. On the
basis of this principle, superparamagnetic iron oxide (and its
analogues) and NaYF4 were selected as the core and shell,
respectively, of the proposed combined system. As a well-
known host material for up-conversion ﬂuorescence, NaYF4
was also reported to be eﬃcient as a substrate for [18F]-ﬂuoride
labeling although the detailed mechanism remains un-
clear.15,25−31 Such a system would allow us to tune the
ﬂuorescent properties by doping the NaYF4 shell with diﬀerent
lanthanide cations, and optimize magnetic properties by
altering the core−shell ratio or the size and composition of
the magnetic core. The bisphosphonate aﬃnity32 of the NaYF4
shell also aﬀords the capability for surface derivatization with
radionuclides and with targeting molecules or polymers to
control solubility and in vivo behavior.
■ RESULTS
Structure, Morphology, Composition, and Colloidal
Stability of NPs. Fe3O4@NaYF4 core/shell NPs were
synthesized by a two-step thermolysis approach using iron
pentacarbonyl and triﬂuoroacetate salts (Scheme S1 in
Supporting Information). Lanthanide cations (Yb, Er, or Tm)
were doped into the NaYF4 shell for the purpose of up-
conversion ﬂuorescence, and Co was doped into the Fe3O4 core
to adjust the magnetic property of NPs. Transmission electron
microscope (TEM) images (Figure 1) revealed that the NPs
with diﬀerent doping shared a similar size and morphology. X-
ray powder diﬀraction (XRD) patterns implied that these
Fe3O4@NaYF4 core/shell NPs consisted of two distinct phases,
Fe3O4 and α-NaYF4 (Figure S1). High resolution transmission
electron micrograph (HRTEM) studies of NPs Fe3O4@
NaYF4(Yb, Tm) showed atomic lattice fringes of 2.97 Å
associated with the (022) and (202) planes of cubic Fe3O4 and
1.72 and 2.94 Å corresponding to the (022) and (200) planes
of cubic NaYF4, respectively (Figure 2a). The angle between
the (022) and (202) planes was calculated as 60°, consistent
with the value measured on the HRTEM image. The electron
diﬀraction patterns were obtained by the fast Fourier transform
analysis of the HRTEM image. Two sets of diﬀraction patterns
for Fe3O4 and NaYF4 were obtained, and each spot was
Figure 1. TEM images at low and high magniﬁcations, and the size
distribution of Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs (a−c) and
Fe3O4@NaYF4(Yb, Tm) NPs (d−f). The particle size was determined
on TEM and N is the number of particles counted for size analysis.
Figure 2. HRTEM studies of NPs: (a) HRTEM images of Fe3O4@
NaYF4(Yb, Tm); (b) fast Fourier transform of the selected area in part
a, showing two sets of diﬀraction patterns. The diﬀraction pattern
marked in blue belonged to cubic Fe3O4, and the one marked in red
was assigned as cubic NaYF4; (c) high angle annular dark ﬁeld image
of Fe3O4@NaYF4(Yb, Tm), showing the Z contrast diﬀerence
between the shell and core of particles induced by a slightly higher
average atomic number in the shell after doping with heavy atoms Yb
and Tm; (d) HRTEM image revealed the core−shell structure of NP
Co0.16Fe2.84O4@NaYF4(Yb, Er). Atomic lattice fringes 2.97 and 4.14 Å
corresponded to (022) and (200) planes of Fe3O4, respectively. The
inset is a fast Fourier transform of the micrograph.
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assigned as indicated in Figure 2b. Analysis of the electron
diﬀraction patterns indicated that core−shell structures were
formed by growing the (011 ̅) plane of NaYF4 on the (111 ̅)
plane of Fe3O4 with a rotation angle of 30°. High angle annular
dark ﬁeld (HAADF, or Z contrast) imaging was employed to
investigate the structure of NP Fe3O4@NaYF4(Yb, Tm), as its
contrast was strongly dependent on average atomic number of
the specimen but insensitive to its thickness. The HAADF
image of Fe3O4@NaYF4(Yb, Tm) NPs in Figure 2c clearly
showed a core/shell structure, in which the Yb- and Tm-
codoped NaYF4 shells appeared brighter than the Fe3O4 cores.
The core−shell structure of Fe3O4@NaYF4 NPs was also
investigated by bright ﬁeld HRTEM. For instance, the HRTEM
image of Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs in Figure 2d
showed a distinct contrast diﬀerence between the Co-doped
Fe3O4 core and the Yb/Er codoped NaYF4 shell, while the
electron diﬀraction pattern indicated the crystalline nature of
the core. Despite the presence of heavy atoms Yb and Er, the
shell appeared brighter on bright ﬁeld TEM image, since the
contrast is determined by the thickness and crystallinity of the
specimen, as well as its elemental composition. The atomic
lattice fringes of 2.97 and 4.14 Å were associated with (022)
and (200) planes, respectively, of the cubic Fe3O4 phase. The
doping of Co into the Fe3O4 lattice, and of Yb and Er into
NaYF4 lattice, was conﬁrmed by energy dispersive X-ray
spectroscopy (EDX) (Figure S2). Compositional studies on
Co/Yb/Er doped NPs were also carried out by X-ray
photoelectron spectroscopy (XPS) and inductively coupled
plasma mass spectrometry (ICP-MS) (Figure S3, Tables S3 and
S4). ICP-MS results indicated a formulation of Co0.16Fe2.84O4
for the core, and the unexpected low Co to Fe ratio was
probably due to an incomplete decomposition of Co(acac)2.
The molar ratio of Y:Yb:Er was measured by ICP-MS as
79.3:18.6:2.1, consistent with the ratio of starting materials
(Y2O3, Yb2O3, and Er2O3). By comparing the relative content
of Fe, Co, Y, Yb, and Er obtained by ICP-MS and XPS (Table
S3), it was clear that dramatically less Fe and Co was detected
by the surface technique XPS, than by ICP-MS or EDX. This is
consistent with the proposed core−shell structure observed by
TEM.
The Co0.16Fe2.84O4@NaYF4(Yb, Er) and Fe3O4@NaYF4(Yb,
Tm) core−shell NPs described above, which are inevitably
covered with oleylamine, were converted to a water-soluble
form by ligand exchange with bisphosphonate polyethylene
glycol conjugates (BP-PEG), as shown in Scheme S1 and
Figure S4. The appearance of characteristic peaks associated
with the PEG chain at 1109, 958, and 837 cm−1 on the IR
spectrum of PEGylated NPs (Figure S5), diﬀraction peaks at
19° and 23° in the XRD pattern (Figure S1),33,34 and a mass
loss of up to 52.7% starting from over 200 °C on
thermogravimetric curves (Figure S6) conﬁrmed the attach-
ment of BP-PEG.
Dynamic light scattering (DLS) experiments demonstrated
that the NPs were highly dispersed in water after surface
modiﬁcation with BP-PEG, showing a hydrodynamic diameter
(Dh) of 44 nm for Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs over a
concentration range from 0.01 to 1 mg/mL. Suspensions of
PEGylated NPs were extremely stable and could not be
precipitated by centrifugation at 10 000 rpm for 30 min. No
aggregation was observed during a period of 14 h by DLS. This
extreme long-term stability is presumed to be due to the strong
coordinative interactions between the bisphosphonate groups
and metallic sites on the surface of NPs, in keeping with earlier
observations.8,21
Radiolabeling of NPs. The NaYF4 shell of NPs was chosen
in part due to a high aﬃnity for [18F]-ﬂuoride, as ﬂuoride
binding to NaYF4 has been reported previously.
27,28 Indeed, the
18F-labeling eﬃciency of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-
PEG NPs (0.1 mg) was up to 38.5% after a brief (5 min)
incubation with aqueous no-carrier-added [18F]-ﬂuoride at
room temperature (Table S5). These observations were
consistent with the core/shell structure of the NPs since
neither Co0.16Fe2.84O4 nor Fe3O4 alone showed signiﬁcant
binding to [18F]-ﬂuoride.35 The labeling eﬃciency (% of
radionuclide bound) was found to increase with the amount of
NPs, which is consistent with previous observations.35 The
serum stability of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG NPs
prelabeled with [18F]-ﬂuoride was determined by incubating
the ﬂuorinated particles in human serum for intervals of up to 2
h and measuring the fraction of activity remaining bound to
NPs with a gamma counter after separating NPs from the
supernatant by centrifugation in a NanoSep device with a cutoﬀ
size of 10K (Figure S7). Over 85% of the 18F remained bound
to the NPs after incubation in serum up to 2 h, slightly less than
ca. 90% reported in PBS (phosphate buﬀered saline).28 The
initial partial release of 18F from NPs into serum seemed to be a
rapid process since no further changes was observed after 15
min.
Because of the previously observed strong interactions
between phosphonate groups and NaYF4 NPs
32 and iron
oxide NPs,33 it was expected that the NPs would have a high
aﬃnity for radiometal chelate−bisphosphonate conju-
gates.8,20,21,33 Both Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG
and Fe3O4@NaYF4(Yb, Tm)-BP-PEG particles showed a high
aﬃnity to 99mTc-DPA-ale (data not shown) and 64Cu-
(DTCBP)2, which has two uncoordinated bisphosphonate
groups,8,20 with up to 96% labeling eﬃciency (Table S5). The
ability to bind readily with [18F]-ﬂuoride and bisphosphonate
conjugates of 64Cu and 99mTc oﬀers potential applications in
PET and SPECT imaging.
Magnetic Resonance Properties. The r1 and r2
relaxivities were measured in aqueous solution at magnetic
ﬁelds of 3 T and 7 T, to determine the feasibility of using these
core/shell structures as MRI contrast agents. The values of
relaxivities r1 and r2 of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG
in aqueous solution at 3 T were calculated as 5 and 102 mM−1
s−1, respectively (Figure 3a). At a higher magnetic ﬁeld (7 T), r1
and r2 were found to be 2 and 159 mM
−1 s−1, respectively.
Fe3O4@NaYF4(Yb, Tm)-BP-PEG NPs showed a r2 relaxivity of
up to 326 mM−1 s−1, and a r1 value of 3 mM
−1 s−1 at 3 T
(Figure S8). A high r2 value and r2/r1 ratio for both
Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG and Fe3O4@NaY-
F4(Yb, Tm)-BP-PEG demonstrated their excellent potential
as T2 or T2* contrast agents in MRI. Indeed, Fe3O4@
NaYF4(Yb, Tm)-BP-PEG NPs, as a multimodal contrast,
provided a higher r2 relaxivity (326 mM
−1 s−1) than clinically
used Feridex (r2 ≈ 107 mM−1 s−1, r2/r1 ≈ 4.65)36 and most
iron oxide or iron nanoparticle-based single-modality T2 MRI
contrast agents reported so far.37−39
Optical Properties. NaYF4 and its paramagnetic analogue
NaGdF4 have been intensively investigated as host materials,
into which rare earth cations can be doped or codoped to
achieve down-conversion or up-conversion ﬂuores-
cence.16,23,40,41 In order to incorporate this type of optical
activity into our multimodality contrast NPs, lanthanide cations
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Er or Tm (active cations) were codoped with Yb3+ (sensitizer)
into the NaYF4 layer. Up-conversion ﬂuorescent emission was
then observed under excitation with a 980 nm laser. Two
emission features for Fe3O4@NaYF4(Yb, Tm)-BP-PEG at 700
and 800 nm were observed and assigned to the transitions 3F3
to 3H6 and
3H4 to
3H6 of Tm
3+ (Figure S9), while three
emission features of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG at
525, 550, and 650 nm, were assigned to the transitions from
2H11/2 to
4I15/2,
4F3/2 to
4I15/2, and
4F9/2 to
4I15/2 of Er
3+ (Figure
3b). To explore the application in ﬂuorescent imaging,
Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG NPs was incubated
in vitro with a cultured monolayer of HeLa cancer cells in
physiological saline for 24 h. Green ﬂuorescent signals from
NPs associated with cytoplasm of living HeLa cells were
observed (Figure 3c), and the deﬁned structure and position of
the green ﬂuorescence consistently identiﬁed cellular uptake of
the NPs. We did not observe any ﬂuorescent signal in the same
dynamic range when a control cell culture was imaged without
NP incubation. Under the high speed raster scan imaging
mode, no random movement was observed and all NPs stay at
the same position, indicating that NPs were incorporated inside
the cells.
In Vivo Studies. To investigate the biodistribution in vivo
of these NPs after systemic (intravenous) administration,
solutions of the 18F-radiolabeled Co0.16Fe2.84O4@NaYF4(Yb,
Er)-BP-PEG (10K) (130 μL, 5.6 MBq, 40 μg Fe) and Fe3O4@
NaYF4(Yb, Tm)-BP-PEG (2K) NPs (150 μL, 3.7 MBq, 45 μg
Fe, Tables S1 and S2) were injected into the tail veins of two
diﬀerent mice, immediately followed by imaging by coregis-
tered PET-MRI on a preclinical nanoScan PET•MRI scanner
with 1 T magnetic ﬁeld (Mediso Ltd., H-1047, Budapest,
Hungary). In both cases, radioactivity was taken up by the
spleen and liver within 45 min, and accumulated to a small
extent in the bladder after 60 min (Figures 4a−d and S10 and
S11). This biodistribution pattern for radioactivity was matched
by darkening contrast observed on MR images (Figure 4e,f).
Very little radionuclide accumulation in the skeleton (character-
istic of free [18F]-ﬂuoride) was observed, indicating that the
NP-radiolabel bond was reasonably stable in vivo over a 1 h
time period. The later increase in radioactivity in the bladder
and bone, which coincided with a decrease of radioactivity in
the liver, suggests that the particles may be degraded in the liver
with release of free ﬂuoride.
In vivo PET/MRI imaging of the lymph node (LN) system
was carried out using a preclinical nanoScan integrated PET/
MRI system (Mediso, Budapest, Hungary) with 1 T magnet,
utilizing 18F-labeled Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG
(10 K) or Fe3O4@NaYF4(Yb, Tm)-BP-PEG (2 K) NPs as
probe. After injection of 20 μL of a solution of these NPs
containing 6.3 MBq radioactivity and 20 μg Fe into the rear
right foot pad of a mouse (C57BL/6, female, 6−7 weeks old, 20
g), coregistered PET and MRI images were recorded 6 h post
injection. The LNs were clearly visible on PET images (Figure
5). The most prominent signal was from the popliteal LN,
which is the nearest draining LN from the injection point, and
the next most prominent signal was from the medial iliac LN
(Figure 5b). Both LNs were evident on the MR image with a
decrease in MR T2 signal intensity compared to the
Figure 3. (a) Curve of relaxivity against the concentration of Fe+Co
for Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG at 3T and 7T) (concen-
tration of Fe and Co determined by ICP-MS); (b) up-conversion
spectrum of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG under excitation
by a 980 nm laser; (c) transmitted infrared image of HeLa cell culture
in monolayer (gray scale) incubated with Co0.16Fe2.84O4@ NaYF4(Yb,
Er)-BP-PEG and ﬂuorescence emission image (green, 490−560 nm)
overlaid. Excitation wavelength 980 nm. Arrows show green
ﬂuorescence from cell-incorporated particles.
Figure 4. PET/MR images showing the dynamic biodistribution of 18F
radiolabeled NPs. MR images were taken immediately after PET scans,
2 h post the injection of NPs, and they were fused with PET images
taken at three diﬀerent time intervals (0−15 min, 45−60 min, and
105−120 min). (a) PET/MR fused image at 0−15 min, showing
radioactivity mainly conﬁned to blood pool with minor uptake in liver;
(b) PET/MRI fused image at 45−60 min showing increased
accumulation in liver and minor uptake in skeleton; and (c) PET/
MR fused image at 105−120 min showing increased uptake in
skeleton and bladder; (d) whole body PET image showing uptake of
radiolabeled negatively charged NPs Co0.16Fe2.84O4@NaYF4(Yb, Er)-
BP-PEG (10K) (maximum intensity projection, 30−45 min), showing
radioactivity mainly conﬁned to blood pool, with little activity in bone
or bladder; (e) MR image of the mouse prior to the injection of
Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG (10K) NPs; (f) MR image of
the mouse 2 h post injection of Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-
PEG (10K) NPs. The series of images (a) to (d) shows predominantly
blood pool retention of the labeled NPs at early stages post injection,
giving way to liver uptake and then bone and bladder, consistent with
release of radioactivity from nanoparticles in liver as free ﬂuoride.
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contralateral (control) LNs (Figure S12). Interestingly, a PET
signal was also detected at the more distant lumbar aortic LN
(Figure 5d and e). However, no contrast was observed at this
area on MR image post injection, due to the relatively poor
sensitivity of MRI (Figures 5c and S12). Because of the long
delay post injection (6 h) skeletal uptake of radioactivity was
also observed in the PET image consistent with gradual release
of ﬂuoride from the NPs in vivo.
To further explore the potential value of this class of NPs, a
more detailed lymph node study by PET/MRI imaging was
undertaken, investigating the popliteal LN in response to an
acute inﬂammatory stimulus in the foot. A solution of 18F
labeled Fe3O4@NaYF4(Yb, Tm)-BP-PEG (20 μL, 4.5 MBq, 20
μg Fe) was injected into each of the two rear footpads of a
female C57BL/6 mouse in which only the right leg was
inﬂamed. Again, uptake of particles in both popliteal and iliac
LNs was identiﬁed by PET and MRI (Figures 6, S13) 6 h post
injection. Interestingly, the right popliteal LN appeared on the
MR image as a white spot with a darkened background while
the left counterpart displayed a black spot with a white
background typical of a healthy lymph node (Figure 6h and i).
A possible biological rationale for this behavior is that the LPS
induced a macrophage response that may have taken up
suﬃcient numbers of the nanoparticles to be detectable by
MRI. As macrophages migrating to draining lymph nodes do
not enter the lymph node, but rather stay in the capsular layer,
this would lead to the observed signal distribution.42,43 Thus,
while PET has the sensitivity to easily locate the relevant lymph
node, MRI provided the resolution lacking in PET to delineate
disease-related and hence potentially diagnostic changes in the
ﬁne structure and distribution of contrast agents in and around
the LN. A control experiment was carried out with [18F]-
ﬂuoride but without NPs, under the same conditions. The PET
image in this case did not show any signal at the lymph nodes
and only the skeleton was seen (Figure 6e and f), conﬁrming
that the PET signal in the LN of the NP-treated mice came
from [18F]-labeled NPs. MRI scanning without injection of the
labeled NPs showed no contrast diﬀerence between the normal
LN and the inﬂamed one.
■ DISCUSSION
We have presented a novel type of inorganic core−shell NP
with built-in magnetic, ﬂuorescent, and radiolabeling properties,
which show potential as probes for MRI, optical imaging, and
PET/SPECT imaging. Stealth features to evade the immune
system and prevent opsonization are required in some imaging
and therapy applications to reduce the oﬀ-target localization
and toxicity of NPs, prolong their circulation time in the blood
pool (where this is desirable) and deliver them to speciﬁc sites.
PEGylation, using the novel bisphosphonate derivative to
anchor the PEG to the NP surface, was employed not only to
stabilize the particles against aggregation in solution by the
steric eﬀect, but also to modify their circulation time.
PEGylated ligands with diﬀerent polymeric chain lengths
Figure 5. PET/MRI images of a normal young C57BL/6 mouse
showing LNs with dual contrast provided by 18F-labeled
Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG: (a) schematic diagram
showing the connections between lymph nodes and the injection
point (mouse in supine position); (b) whole body PET image showing
uptake of radiolabeled NPs 7 h post injection (maximum intensity
projection, mice in prone position); (c) MR image with darkening
contrast at popliteal LN (coronal section); (d) PET image showing
radioactivity at popliteal, inguinal, lumbar aortic, and aorta LN area
(coronal section); and (e) PET/MRI fused image showing popliteal,
inguinal, lumbar aortic, and aorta LN (coronal section). Some bone
uptake of radioactivity is observed in (b), (d), and (e) due to gradual
release of ﬂuoride from the particles due to the long delay (7 h post
injection of 18F radiolabeled NPs) between injection and imaging.
Figure 6. Lymph node PET/MRI imaging of a mouse with inﬂamed
right leg using 18F-labeled Fe3O4@NaYF4(Yb, Tm)-BP-PEG NPs (a−
d) or with [18F]-ﬂuoride only (e−g): (a) whole body PET image
showing uptake of radiolabeled NPs (maximum intensity projection;
bone uptake was observed due to gradual release of ﬂuoride from NPs
due to the 7 h delay post injection of NPs); (b) PET image showing
popliteal and iliac lymph nodes (coronal section); (c) PET/MRI fused
image (coronal section); (d) MR image (coronal section) with
darkening contrast inside popliteal lymph node at left-rear (white
circle) and “outside” lymph node at the inﬂamed right-rear (red circle)
induced by injection of 30 μL 0.67 mg/mL lipopolyscchrade (LPS) 18
h prior to imaging, and at iliac lymph node; (e) PET image following
injection of [18F]-ﬂuoride showing no contrast in lymph nodes in the
absence of NPs and prominent uptake by skeleton; (f) PET/MRI
fused image following injection of [18F]-ﬂuoride, showing no
radioactivity associated with lymph nodes; (g) MR image showing
no diﬀerence between normal popliteal lymph node at left-rear leg
(white circle) and the inﬂamed lymph node at right-rear leg induced
by injection of 30 μL 0.67 mg/mL LPS 18 h prior to imaging; and (h−
k) enlarged MR images of corresponding lymph nodes.
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were introduced on the surface of Co0.16Fe2.84O4@NaYF4(Yb,
Er) and Fe3O4@NaYF4(Yb, Tm) NPs, to produce water-
soluble versions: Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG and
Fe3O4@NaYF4(Yb, Tm)-BP-PEG. In both cases, PEGylation,
small hydrodynamic size (≪100 nm) and low zeta-potential44
oﬀer the opportunity to control circulation time and avoid
immediate reticulendothelial clearance where this is desired for
speciﬁc applications. Indeed, the longer-chain PEGylation of
Co0.16Fe2.84O4@NaYF4(Yb, Er) (10 K) (Mw = 10 kDa, n ≈
227) resulted in a slightly negative zeta potential (−10 mV)
and delayed clearance compared to Fe3O4@NaYF4(Yb, Tm)-
BP-PEG (2 K) (Mw = 2 kDa, n ≈ 45, and zeta potential of +10
mV)) (Figures 4, S10 and S11), although surface density of
PEG(10K) is less than that of PEG(5K) (37.6% vs 52.7%).
This suggests that the length of the PEG chain and zeta
potential of NPs play important roles in biodistribution. The
circulation time of Co0.16Fe2.84O4@NaYF4(Yb, Er) (10 K) is
shorter than that reported previously for PEGylated iron
oxide.30 This may be attributable to reduced PEG surface
coverage (36.7% vs 61%, Figure S6). The extent of PEGylation
and the chain length may therefore be optimized for speciﬁc
applications. Particle size combined with surface properties also
plays an important role in enhancing lymphatic transport.45,46
Small particles (less than 100 nm) are transported and taken up
more readily, whereas the larger NPs are likely to remain in the
injection site. PEGylation can improve the uptake in lymph
nodes by reducing the nonspeciﬁc interaction between particles
and proteins of the interstitium.
Convenient incorporation of readily available imaging
radioisotopes such as [18F]-ﬂuoride is important for applica-
tions in radionuclide imaging. Because of the short half-life and
the need for GMP conditions in the daily production of
radiopharmaceuticals at hospital sites, radiolabeling procedures
must be as simple as possible and avoid the requirement of
costly specialist facilities. Inorganic nanoparticulate materials
have previously been reported that bind [18F]-ﬂuoride rapidly
with high eﬃciency under mild conditions.35 The NaYF4 shell
of the core−shell system can eﬃciently carry 18F as well as
other radionuclides such as 99mTc or 64Cu BP conjugates, and
the radiolabeling of these particles is extremely simple, quick,
and eﬃcient. Release of ﬂuoride from the NPs, allowing uptake
in bone, is relatively slow compared to both lymphatic transport
and reticulendothelial clearance, allowing imaging of both
processes (Figures 4−6, S10 and S13).
The ﬂuorescent properties of the codoped NaYF4 shell
allowed microscopic ﬂuorescence imaging at the cellular level
(Figure 3d), and could be explored as a potential visual guide
during surgery.47 NPs with stronger ﬂuorescent emissions can
be developed by deposition of additional pure or doped NaYF4
layer on the core−shell structures22 to suppress the energy
transfer to surface quenchers (impurities, ligands, and solvent
molecules) and to modify local crystal structure surrounding
the doping cations. The balance between the thickness of the
ﬂuorescent and radiolabeled shell of NaYF4 and the size and
composition of the magnetic core could be adjusted to optimize
the optical and magnetic properties, respectively, for
applications as multimodal imaging agents.48 For example,
NPs Fe3O4@NaYF4(Yb, Tm)-BP-PEG showed a much higher
r2 relaxivity than NPs Co0.16Fe2.84O4@NaYF4(Yb, Er)-BP-PEG
(326 mM−1 S−1 vs 102 mM−1 S−1), though both of them share
a similar particle size and core-to-shell ratio (Figure S9).
Accurate location and identiﬁcation of lymph nodes and
detection of the pathology within them is important for studies
of tumor metastasis in humans, including the identiﬁcation of
sentinel lymph nodes during surgery, and in rodent models for
the study of immune responses to foreign antigens, transplants,
and tumors. The in vivo imaging studies reported here,
although not matched to a current typical clinical imaging
protocol, are relevant to sentinel node imaging in support of
cancer surgery and suggest several ways in which combined
coregistered MR and PET imaging with a single contrast agent
can provide additional information and increased conﬁdence in
image interpretation. The PET images, by virtue of lower
content of irrelevant detail, allow easy identiﬁcation of regions
for closer examination by MRI. In addition, the greater
sensitivity of PET allows detection of relevant lymph nodes
distant from the disease site (e.g., Figure 5c−e) which is
unlikely to be detected by MRI alone (Figure 6). The accurate
presurgical location of iliac and popliteal LNs in context of the
anatomy of the mouse was achieved only when the PET and
MRI images were coregistered and overlaid. The improved soft
tissue contrast oﬀered by MRI compared to CT, which is
conventionally combined with PET and SPECT, should oﬀer
improved presurgical mapping of lymph node locations.
Moreover, the additional anatomical and functional detail in
soft tissues permitted by contrast MRI (e.g., the diﬀerences in
structure and contrast agent distribution in and around the
lymph node between left and right popliteal nodes) in regions
initially identiﬁed by PET, but which the limited resolution of
PET cannot show, have the potential to provide useful
diagnostic information beyond simply identifying presurgically
the location of the sentinel node. This is likely to provide
synergistic value when used during imaging with the new
generation of clinical combined PET/MR scanners now
appearing in hospitals. The ﬂuorescence should enable further
visual observation of these anatomical and functional changes
during surgery and subsequently during pathological examina-
tion of excised tissues. Data from each of these imaging
modalities can be combined, with reassurance that the signal
comes from the same contrast agent, and hence the same
biodistribution, in each modality.
■ CONCLUSIONS
In summary, we have reported the synthesis and character-
ization of the ﬁrst series of CoxFe3‑xO4@NaYF4 core−shell
based NPs in which the shell was codoped with lanthanide
cations providing optical imaging capabilities, and could also be
radiolabeled with [18F]-ﬂuoride and radiometal−bisphospho-
nate conjugates, while the iron oxide-based core provided MR
contrast. We have shown for the ﬁrst time that the NaYF4 shell
can be stably modiﬁed with bisphosphonate-derived PEG and
radionuclide conjugates. The particles oﬀer trimodal imaging
using PET/SPECT, MRI, and up-conversion ﬂuorescent
imaging. The NPs showed excellent colloidal stability in
water and a narrow size distribution after surface modiﬁcation
with BP-PEG. The simple and quick radiolabeling process is a
major advantage for use of these materials as PET/SPECT
tracers and is essential for routine clinical use. Our in vivo
studies in lymph nodes demonstrated the potential advantages
of combining imaging modalities using NPs as multimodal
(PET, MRI, and optical) imaging agents. In addition, these NPs
could also potentially act as visual guides during surgery due to
their up-conversion ﬂuorescent properties.
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■ EXPERIMENTAL SECTION
Materials and General Characterization. Chemicals
were obtained from commercial sources and used as purchased
without further puriﬁcation unless otherwise speciﬁed. Human
serum was obtained by ﬁltering human male AB plasma from
Sigma-Aldrich with Millex IC 0.22 μm (13 mm) hydrophilic
PTFE ﬁlters. Water was obtained from an ELGA PureLab
OptionQ system. Organic solvents oleylamine (90%, technical
grade) and 1-octadecene (90%, technical grade) came from
Fisher Scientiﬁc Ltd. Rare earth triﬂuoroacetate salts were
prepared in house from corresponding rare earth oxides
purchased from Sigma-Aldrich. Typically, the mixed powder
of Y2O3, Yb2O3, and Er2O3 (molar ratio Y:Yb:Er = 78:20:2) was
dissolved in triﬂuoroacetic acid at 60 °C, and water was
removed by rotary evaporator to obtain light pink or white
M(CF3COO)3 powder.
18F and 64Cu were produced using the
PET Imaging Centre cyclotron at St Thomas’s Hospital,
London, UK. 99mTc-MDP was obtained from the Nuclear
Medicine Department, Guy’s and St Thomas’ Foundation
Trust. Thermogravimetric analysis (TGA) was performed
under a ﬂow of nitrogen (20 mL/min) with a heating rate of
5 °C/min using a TA SDT-600 thermogravimetric analyzer.
XRD were recorded at room temperature on a PANalytical
X’Pert PRO diﬀractometer using Cu Kα1 radiation (λ =
1.540598 Å) at 40 kV, 40 mA, at a scan speed of 0.02°/s and a
step size of 0.026° in 2θ. XPS spectra were recorded using a
Kratos AXIS ULTRA with monochromated Al K radiation (10
kV anode potential, 15 A emission current) in ﬁxed analyzer
transmission mode (80 eV pass energy). TEM images were
taken on Tecnai FEI T20 at Centre for Ultrastructural Imaging,
King’s College London, and HRTEM on JEOL 2100 at
Nottingham Nanotechnology and Nanoscience Centre, Not-
tingham University, and on T20 at LEMAS, Leeds University.
IR spectra were recorded on a PerkinElmer spectrum 100. DLS
experiments were carried out on Zetasizer Nano ZS from
Malvern Instruments with a measured angle 175° and a 632.8
nm laser. Zeta potential for all samples was measured in neutral
aqueous solution with a pH value ≈ 7. Up-conversion spectra
were obtained at Queen Mary University of London, using a
980 nm continuous wave diode laser modulated at a frequency
of 13 Hz. The photoluminescence was dispersed in a Triax 550
spectrometer and detected with a Hamamatsu R5509−72
photomultiplier.
Synthesis of Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs. First,
Co(acac)2 (514 mg, 2 mmol) was dissolved in a solvent mixture
of 5 mL oleylamine and 15 mL 1-octadecene at 120 °C under
vacuum. Under N2 atmosphere, Fe(CO)5 (4.5 mmol, 0.6 mL)
was injected into the solution of Co(acac)2, and then the
resultant solution was heated up to 250 °C within 15 min under
stirring. After being kept at 250 °C for 1 h, a solution obtained
by dissolving CF3COONa (800 mg, 5.9 mmol) and M-
(CF3COO)3 (M = Y, Yb, or Er; Y:Yb:Er = 78:20:2; 1000 mg; 2
mmol) in 10 mL oleyl amine and 10 mL 1-octadecene at 120
°C under vacuum, was added into the resultant black slurry
under N2 by syringe. The mixture was heated to 340 °C with a
heating rate 10 °C/min. After being kept at 340 °C for 15 min,
the mixture was cooled down to room temperature by
removing the heating bath. The product was precipitated out
by adding 30 mL ethanol and then collected by a magnet. The
particles were redispersed in hexane and precipitated with
ethanol twice more. Fe3O4@NaYF4(Yb, Tm) NPs was obtained
use a similar approach as Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs.
Synthesis of Fe3O4@NaYF4(Yb, Tm) NPs. First,
CF3COONa (800 mg, 5.9 mmol) and M(CF3COO)3 (M =
Y, Yb, or Tm; Y:Yb:Tm = 75:20:5; 1000 mg; 2 mmol) were
dissolved in 10 mL oleyl amine and 10 mL 1-octadecene at 120
°C under vacuum for at least 30 min. Under N2 atmosphere,
Fe(CO)5 (7 mmol, 0.9 mL) was injected into the solution, and
then the resultant solution was heated up to 200 °C within 15
min under stirring. The mixture was maintained at 200 °C for
20 min under N2, and then heated to 340 °C with a heating rate
10 °C/min. After being kept at 340 °C for 1 h, the mixture was
cooled down to room temperature by removing the heating
bath. The product was precipitated out by adding 30 mL
ethanol and then collected by a magnet. The particles were
redispersed in hexane and precipitated with ethanol twice more.
PEGylation of NPs. BP-PEG prepared as described
elsewhere8 (10 kDa, 20 mg) was dissolved in a mixture of
methanol (16 mL) and ethanol (4 mL), and then 3 mL of a
hexane suspension containing ca. 60 mg synthesized
Co0.16Fe2.84O4@NaYF4(Yb, Er) NPs was added under soni-
cation using a standard laboratory sonic bath. The resultant
brown solution was treated with excess hexane to precipitate
out NPs. To remove uncoordinated ligands, the product was
redispersed in ethanol and precipitated out by adding hexane.
The same procedure was carried out to conjugate BP-PEG (2
kDa) with Fe3O4@NaYF4(Yb, Tm) NPs.
Radiolabeling of NPs with [18F]-Fluoride, 99mTc-DPA-
ale, or 64Cu-(DTCBP)2. Typically, 100 μL of [
18F]-ﬂuoride in
18O-water direct from target was added into a Nanosep
centrifugal device with omega membrane (from Sigma-Aldrich,
molecular weight cutoﬀ size = 30 000) containing 400 μL NP
suspension. After incubation at room temperature for 5−15
min, the suspension was centrifuged at 10 000 rpm (Eppendorf
centrifuge 5424) for 10 min to separate the NPs from solution.
The radioactivity remaining in ﬁltrate and on NPs was
measured by a gamma counter or a CRC-25R dose calibrator
(Capintec, USA). Labeling eﬃciency was calculated by dividing
the radioactivity on NPs by the sum of that in supernatant and
on NPs. Triplicate measurements were carried out at each
concentration of NPs. Radiolabeling with 99mTc-DPA-ale or
64Cu bis(dithiocarmabate) bisphosphonate conjugate (64Cu-
(DTCBP)2) was carried out via the previously published
procedures.8,21
Stability of [18F]-Fluoride Labeled NPs in Human
Serum. 18F-Fluoride labeled radiolabeled NPs were dissolved
in 500 μL serum and left at 37 °C for diﬀerent periods of time.
Then NPs were separated by Nanosep centrifugation at 14 000
rpm (Eppendorf centrifuge 5424) for at least 15 min. The
radioactivity in serum and on NPs was measured by gamma
counter, respectively. Triplicate samples were measured at each
time point.
T1, T2, and T2* Relaxivity Measuremen. MR imaging was
performed with a standard extremity ﬂex coil on a clinical 3T
Philips Achieva MRI scanner (Philips Healthcare, Best, The
Netherlands). T1 mapping was obtained by using a 2D
sequence that employs two nonselective inversion pulses with
inversion times ranging from 20 to 2000 ms, followed by eight
segmented readouts for eight individual images.49 The two
imaging trains result in a set of 16 images per slice with
increasing inversion times (FOV = 200 × 200 mm2, matrix =
200 × 179 mm2, in-plane resolution = 1 × 1.12 mm2, measured
slice thickness = 3 mm, slices = 16, TR/TE = 3.2/1.6 ms, FA =
10°). T2 was determined with a 2D multispin−echo sequence
(FOV = 200 × 200 mm, matrix = 200 × 200, measured slice
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thickness = 3 mm, ETL = 5, TE = 10 ms, TR = 725 ms, FA =
90°). The acquired imaging data were transferred to a
computer running Matlab and analyzed using an in-house
Matlab tool to receive the relaxation times T1 and T2 for each
SPIO concentration. Excel was used to plot the relaxation rates
over the concentration and to ﬁt a linear function to determine
the relaxivity values (i.e., gradient of linear ﬁt).
In Vivo PET/MRI Imaging. Five 6−7-week-old female C57
black mice with a weight of 20−21 g were used. Animal
experiments were carried out at Nanobiotechnology & In Vivo
Imaging Center of Semmelweis University, with permission
from the local institutional animal ethics committee and in
compliance with the relevant European Union and Hungarian
regulations. Inﬂammation was induced by injection of 30 μL
0.67 mg/mL lipopolysaccharide (LPS) into the footpad of the
right-rear leg, 18 h prior to the injection of NPs. PET/MRI
images were recorded on a nanoScan integrated PET/MRI
system (Mediso, Budapest, Hungary) in which the MR is a
preclinical 1T MRI scanner (M2, Aspect Imaging) with
horizontal bore magnet, solenoid coil (diameter of 35 mm),
and 450 mT/m gradients. Mice were anaesthetized with
isoﬂurane and placed in prone position on the MRI bed. In the
case of lymph node imaging with NP Co0.16Fe2.84O4@
NaYF4(Yb, Er)-BP-PEG, after the precontrast MR scan, 20
μL NPs solution in saline containing 6.3 MBq 18F-ﬂuoride
radioactivity and 40 μg Fe was injected into the footpad of the
right-rear leg (Tables S1 and S2). PET scanning was started 6 h
after injection. Acquisition took place in 1−5 coincidence mode
with 5 ns coincidence window, 400−600 keV energy window,
94.7 mm scan range, and acquisition time was 30 min. A 3D
expectation maximization (3D EM) PET reconstruction
algorithm (Mediso Tera-Tomo TM) was applied to produce
PET images including corrections for attenuation and scatter,
dead time, decay, and randoms. After 8 iterations the
reconstruction stopped, resulting in images with 0.1 mm
voxel size and time frames of 8 × 15 min. MR scanning was
performed immediately after PET. The images of the two
modalities were fused automatically. The same procedure was
carried out for intravenously injected contrast agent, but
radiolabeled nanoparticles were injected via the tail vein and
PET scanning started immediately after the injection with total
acquisition time of 2 h instead of 30 min.
In Vitro Fluorescent Cell Imaging. A monolayer HeLa
cell culture (grown in RPMI 1640 medium supplemented with
2% of fetal calf serum) was incubated for 24 h with the
nanoparticle dispersion. Particles that were not attached or
internalized to cells were washed by physiological saline. Cell
culture was imaged in the Femto2D two-photon microscope,
under an excitation laser of 980 nm. We also imaged a washed
but not nanoparticle-incubated control HeLa cell monolayer in
the same conditions. Z-stacks of 1 μm z-steps at 35 μm z-range
were recorded in both cases in order to ﬁnd the inner part of
the cells. A few diﬀusing particles in the solution above the cells
were clearly distinguishable from those that did not move,
attached inside the cells. Transmitted infrared light and green
ﬂuorescence emission (490−560 nm) was detected in separate
channels.
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